1. Home
  2. MUC vs JANX Comparison

MUC vs JANX Comparison

Compare MUC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniHoldings California Quality Fund Inc.

MUC

Blackrock MuniHoldings California Quality Fund Inc.

HOLD

Current Price

$10.72

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$14.06

Market Cap

790.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUC
JANX
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
790.3M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
MUC
JANX
Price
$10.72
$14.06
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$53.60
AVG Volume (30 Days)
243.5K
757.7K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$209.90
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.97
$12.12
52 Week High
$11.04
$35.34

Technical Indicators

Market Signals
Indicator
MUC
JANX
Relative Strength Index (RSI) 38.37 52.44
Support Level $10.71 $13.80
Resistance Level $10.78 $14.46
Average True Range (ATR) 0.09 0.56
MACD -0.02 0.06
Stochastic Oscillator 8.57 69.80

Price Performance

Historical Comparison
MUC
JANX

About MUC Blackrock MuniHoldings California Quality Fund Inc.

BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes. The fund mainly invests in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and California personal income taxes. Under normal market conditions, it invests a majority of its managed assets in investment-grade municipal obligations with remaining maturities of one year or more at the time of investment. It can also invest in below investment-grade securities, or directly in such securities or synthetically through the use of derivatives.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: